ALIM Alimera Sciences Inc.

0.4
+0.01  (+3%)
Previous Close 0.39
Open 0.39
Price To Book -0.83
Market Cap 28,403,760
Shares 71,009,400
Volume 224,011
Short Ratio
Av. Daily Volume 281,270
Stock charts supplied by TradingView

NewsSee all news

  1. Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    ATLANTA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  2. Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    ATLANTA, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  3. Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  4. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    ATLANTA, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  5. Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    ATLANTA, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  2. Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    ATLANTA, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  3. Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  4. Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    ATLANTA, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  5. Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

  6. Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    ATLANTA, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal